Is Development of a Vaccine against Feasible?

1. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harbor perspectives in medicine. 2014;4(7):a019760. doi: 10.1101/cshperspect.a019760 24985132

2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids. 2009;23(4):525–30. Epub 2009/02/03. doi: 10.1097/QAD.0b013e328322ffac 19182676

3. Hole CR, Wormley FL Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol. 2012;3:291. doi: 10.3389/fmicb.2012.00291 22973262

4. Chaturvedi AK, Wormley FL Jr. Cryptococcus antigens and immune responses: implications for a vaccine. Expert review of vaccines. 2013;12(11):1261–72. doi: 10.1586/14760584.2013.840094 24156284

5. Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence. Future microbiology. 2010;5(8):1269–88. doi: 10.2217/fmb.10.93 20722603

6. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007;7(6):395–401. 17521592

7. Casadevall A, Pirofski LA. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell host & microbe. 2012;11(5):447–56.

8. Datta K, Subramaniam K. Host Defense Against Cryptococcal Disease: Is there a Role for B cells and Antibody-Mediated Immunity. Current fungal infection reports. 2014;8:287–95.

9. Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. Journal of immunology. 2005;174(12):7920–8. 15944298

10. Wormley FL Jr., Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun. 2007;75(3):1453–62. 17210668

11. Wozniak KL, Young ML, Wormley FL Jr. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol. 2011;18(5):717–23. doi: 10.1128/CVI.00036-11 21450975

12. Wozniak KL, Levitz SM. Isolation and purification of antigenic components of Cryptococcus. Methods Mol Biol. 2009;470:71–83. doi: 10.1007/978-1-59745-204-5_7 19089377

13. Leopold Wager CM, Wormley FL. Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol. 2014;7(5):1023–35. doi: 10.1038/mi.2014.65 25073676

14. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. Journal of immunology. 2005;174(10):6346–56. 15879135

15. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. Journal of immunology. 2007;179(8):5367–77. 17911623

16. Hardison SE, Ravi S, Wozniak KL, Young ML, Olszewski MA, Wormley FL Jr. Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am J Pathol. 2010;176(2):774–85. doi: 10.2353/ajpath.2010.090634 20056835

17. Hardison SE, Wozniak KL, Kolls JK, Wormley FL Jr. Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect Immun. 2010;78(12):5341–51. doi: 10.1128/IAI.00845-10 20921149

18. Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. Journal of immunology. 2012;189(8):4060–8. doi: 10.4049/jimmunol.1103455 22984078

19. Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Wormley FL Jr. STAT1 Signaling Is Essential for Protection against Cryptococcus neoformans Infection in Mice. Journal of immunology. 2014;193(8):4060–71. doi: 10.4049/jimmunol.1400318 25200956

20. Hole CR, Bui H, Wormley FL Jr., Wozniak KL. Mechanisms of dendritic cell lysosomal killing of Cryptococcus. Scientific reports. 2012;2:739. doi: 10.1038/srep00739 23074646

21. Kelly RM, Chen J, Yauch LE, Levitz SM. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun. 2005;73(1):592–8. 15618199

22. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun. 2006;74(7):3817–24. 16790753

23. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect Immun. 2008;76(10):4764–71. doi: 10.1128/IAI.00660-08 18678670

24. Lewis KL, Reizis B. Dendritic cells: arbiters of immunity and immunological tolerance. Cold Spring Harbor perspectives in biology. 2012;4(8):a007401. doi: 10.1101/cshperspect.a007401 22855722

25. Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host-pathogen interface. Nature immunology. 2006;7(2):117–20. 16424884

26. Nakamura K, Miyazato A, Xiao G, Hatta M, Inden K, Aoyagi T, et al. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. Journal of immunology. 2008;180(6):4067–74. 18322216

27. Weitnauer M, Schmidt L, Ng Kuet Leong N, Muenchau S, Lasitschka F, Eckstein V, et al. Bronchial epithelial cells induce alternatively activated dendritic cells dependent on glucocorticoid receptor signaling. Journal of immunology. 2014;193(3):1475–84. doi: 10.4049/jimmunol.1400446 24965772

28. Cook PC, Jones LH, Jenkins SJ, Wynn TA, Allen JE, MacDonald AS. Alternatively activated dendritic cells regulate CD4+ T-cell polarization in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(25):9977–82. doi: 10.1073/pnas.1121231109 22660926

29. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell host & microbe. 2011;9(5):355–61.

30. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(43):17537–42. doi: 10.1073/pnas.1202870109 22988082

31. Quintin J, Saeed S, Martens JH, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C, et al. Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell host & microbe. 2012;12(2):223–32.

32. Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio. 2013;4(3):e00264–13. doi: 10.1128/mBio.00264-13 23781069